As the S&P 500 nears a record high and airline stocks soar following strong earnings reports, investors are keeping a close eye on global trade developments and tariff uncertainties. In this context, penny stocks—often smaller or newer companies—still hold potential for growth when supported by sound financials. These stocks can offer a mix of value and growth opportunities that larger firms may overlook. Below, we'll explore several penny stocks that stand out for their financial strength, offering promising prospects for those interested in under-the-radar investments.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Rewards & Risks |
| Waterdrop (WDH) | $1.42 | $517.18M | ✅ 4 ⚠️ 0 View Analysis > |
| WM Technology (MAPS) | $0.9386 | $154.96M | ✅ 4 ⚠️ 1 View Analysis > |
| Perfect (PERF) | $2.34 | $241.38M | ✅ 3 ⚠️ 0 View Analysis > |
| Talkspace (TALK) | $2.78 | $456.77M | ✅ 4 ⚠️ 2 View Analysis > |
| Tuniu (TOUR) | $0.9326 | $99.78M | ✅ 3 ⚠️ 2 View Analysis > |
| Safe Bulkers (SB) | $3.77 | $384.69M | ✅ 2 ⚠️ 3 View Analysis > |
| Sequans Communications (SQNS) | $2.07 | $52.57M | ✅ 4 ⚠️ 4 View Analysis > |
| BAB (BABB) | $0.85 | $6.17M | ✅ 2 ⚠️ 3 View Analysis > |
| North European Oil Royalty Trust (NRT) | $4.90 | $45.95M | ✅ 2 ⚠️ 2 View Analysis > |
| TETRA Technologies (TTI) | $3.54 | $467.09M | ✅ 4 ⚠️ 2 View Analysis > |
Click here to see the full list of 421 stocks from our US Penny Stocks screener.
Let's uncover some gems from our specialized screener.
Kodiak Sciences (KOD)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for retinal diseases, with a market cap of approximately $205.26 million.
Operations: Kodiak Sciences Inc. currently does not report any revenue segments.
Market Cap: $205.26M
Kodiak Sciences, a clinical-stage biopharmaceutical company, remains pre-revenue with no significant revenue streams. Despite its seasoned management team and board, the company faces financial challenges with a negative return on equity and increasing losses over the past five years. Kodiak's short-term assets exceed its short-term liabilities but fall short of covering long-term liabilities. The company is debt-free yet highly volatile in share price, which is common for penny stocks. Recent earnings reported a net loss of US$57.46 million for Q1 2025, highlighting ongoing profitability challenges amid presentations at key industry conferences to engage investors and stakeholders.
- Dive into the specifics of Kodiak Sciences here with our thorough balance sheet health report.
- Assess Kodiak Sciences' future earnings estimates with our detailed growth reports.
Design Therapeutics (DSGN)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on researching, designing, developing, and commercializing small molecule therapeutic drugs for genetic diseases in the United States with a market cap of $206.64 million.
Operations: Currently, there are no reported revenue segments for this clinical-stage biopharmaceutical company.
Market Cap: $206.64M
Design Therapeutics is a pre-revenue clinical-stage biopharmaceutical company with a market cap of US$206.64 million, focusing on genetic diseases. The company recently dosed its first Friedreich ataxia patient in an open-label Phase 1/2 trial for DT-216P2, though it faces a clinical hold from the FDA due to nonclinical deficiencies. Despite having no debt and sufficient cash runway for over three years, Design's share price remains highly volatile. With recent losses increasing and no profitability forecast in the near term, the company continues to engage investors through conference presentations while advancing its pipeline.
- Click here to discover the nuances of Design Therapeutics with our detailed analytical financial health report.
- Evaluate Design Therapeutics' prospects by accessing our earnings growth report.
Vimeo (VMEO)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Vimeo, Inc., along with its subsidiaries, offers video software solutions both in the United States and internationally, with a market cap of approximately $661.45 million.
Operations: The company generates $415.13 million in revenue from its Internet Software & Services segment.
Market Cap: $661.45M
Vimeo, Inc., with a market cap of US$661.45 million, has been added to multiple Russell Growth Indexes, signaling increased visibility among investors. The company reported US$103.03 million in Q1 2025 revenue but faced a net loss of US$3.92 million, reflecting challenges in profitability as profit margins decreased from the previous year. Despite negative earnings growth over the past year and low return on equity at 4.5%, Vimeo remains debt-free with strong short-term asset coverage of liabilities and forecasts suggest potential earnings growth at 34.81% annually. Recent executive changes may influence strategic direction moving forward.
- Navigate through the intricacies of Vimeo with our comprehensive balance sheet health report here.
- Examine Vimeo's earnings growth report to understand how analysts expect it to perform.
Summing It All Up
- Dive into all 421 of the US Penny Stocks we have identified here.
- Looking For Alternative Opportunities? The end of cancer? These 24 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Vimeo might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com